Cachexia

• 

  Subject Areas on Research

  • A pathogenetic role for TNF alpha in the syndrome of cachexia, arthritis, and autoimmunity resulting from tristetraprolin (TTP) deficiency. 
  • Activity level, apoptosis, and development of cachexia in Apc(Min/+) mice. 
  • Anamorelin in patients with non-small-cell lung cancer and cachexia (ROMANA 1 and ROMANA 2): results from two randomised, double-blind, phase 3 trials. 
  • Body Mass Index Is Prognostic in Metastatic Colorectal Cancer: Pooled Analysis of Patients From First-Line Clinical Trials in the ARCAD Database. 
  • Cachexia and aging: an update based on the Fourth International Cachexia Meeting. 
  • Cachexia: a new definition. 
  • Cancer Cachexia: Beyond Weight Loss. 
  • Cancer cachexia syndrome in head and neck cancer patients: Part II. Pathophysiology. 
  • Cancer cachexia syndrome in head and neck cancer patients: part I. Diagnosis, impact on quality of life and survival, and treatment. 
  • Cancer cachexia: Are we ready to take a step forward? 
  • Clinical problem-solving. Needle in a haystack. 
  • Clinical results in cachexia therapeutics. 
  • Comparison of animal models for head and neck cancer cachexia. 
  • Consensus on cachexia definitions. 
  • Correlation between the international consensus definition of the Cancer Anorexia-Cachexia Syndrome (CACS) and patient-centered outcomes in advanced non-small cell lung cancer. 
  • Defining cancer cachexia in head and neck squamous cell carcinoma. 
  • Diabetic neuropathic cachexia and diabetic amyotrophy. 
  • Editorial: Megestrol acetate use for weight gain should be carefully considered. 
  • Effects of a gut pathobiont in a gnotobiotic mouse model of childhood undernutrition. 
  • Elevated body mass index predicts for longer overall survival duration in men with metastatic hormone-refractory prostate cancer. 
  • Elevated serum levels of tumor necrosis factor are associated with progressive encephalopathy in children with acquired immunodeficiency syndrome. 
  • Exosomes in Pancreatic Cancer: from Early Detection to Treatment. 
  • Glutamine as indispensable nutrient in oncology: experimental and clinical evidence. 
  • Growth failure and AIDS-like cachexia syndrome in HIV-1 transgenic mice. 
  • Gut barrier dysfunction in the Apc(Min/+) mouse model of colon cancer cachexia. 
  • Gut hormones, appetite suppression and cachexia in patients with pulmonary TB. 
  • Hydrazine sulfate in cancer patients with weight loss. A placebo-controlled clinical experience. 
  • Immunocompetent murine model of cancer cachexia for head and neck squamous cell carcinoma. 
  • In experimental chronic kidney disease or cancer, parathyroid hormone is a novel mediator of cachexia. 
  • Increased myocellular lipid and IGFBP-3 expression in a pre-clinical model of pancreatic cancer-related skeletal muscle wasting. 
  • Influence of total parenteral nutrition on tumor growth and polyamine biosynthesis of fibrosarcoma-bearing rats after induced cachexia. 
  • Megestrol acetate in pediatric oncology patients may lead to severe, symptomatic adrenal suppression. 
  • Muscle mTORC1 suppression by IL-6 during cancer cachexia: a role for AMPK. 
  • Muscle oxidative capacity during IL-6-dependent cancer cachexia. 
  • Muscle wasting and interleukin-6-induced atrogin-I expression in the cachectic Apc ( Min/+ ) mouse. 
  • Muscle wasting in cancer cachexia: clinical implications, diagnosis, and emerging treatment strategies. 
  • Nutrition modulation of gastrointestinal toxicity related to cancer chemotherapy: from preclinical findings to clinical strategy. 
  • Nutrition, Obesity, and Cachexia in Patients With Heart Failure: A Consensus Statement from the Heart Failure Society of America Scientific Statements Committee. 
  • Overcoming obstacles in the design of cancer anorexia/weight loss trials. 
  • Oxidative phenotype protects myofibers from pathological insults induced by chronic heart failure in mice. 
  • PTH/PTHrP Receptor Mediates Cachexia in Models of Kidney Failure and Cancer. 
  • Phase I clinical study of fish oil fatty acid capsules for patients with cancer cachexia: cancer and leukemia group B study 9473. 
  • Phase II study of high-dose fish oil capsules for patients with cancer-related cachexia. 
  • Randomized double-blind placebo-controlled trial of cisplatin and etoposide plus megestrol acetate/placebo in extensive-stage small-cell lung cancer: a North Central Cancer Treatment Group study. 
  • Regulation of inflammation in the adipose tissue in cancer cachexia: effect of exercise. 
  • Research priorities in cancer cachexia: The University of Rochester Cancer Center NCI Community Oncology Research Program Research Base Symposium on Cancer Cachexia and Sarcopenia. 
  • Results of a pilot study of the effects of celecoxib on cancer cachexia in patients with cancer of the head, neck, and gastrointestinal tract. 
  • Skeletal muscle disease in rheumatoid arthritis: the center of cardiometabolic comorbidities? 
  • Skeletal muscle loss: cachexia, sarcopenia, and inactivity. 
  • Study Design and Rationale for the Phase 3 Clinical Development Program of Enobosarm, a Selective Androgen Receptor Modulator, for the Prevention and Treatment of Muscle Wasting in Cancer Patients (POWER Trials). 
  • The effect of altered Toll-like receptor 4 signaling on cancer cachexia. 
  • The regulation of skeletal muscle protein turnover during the progression of cancer cachexia in the Apc(Min/+) mouse. 
  • Tumour-derived PTH-related protein triggers adipose tissue browning and cancer cachexia. 
  • Unintentional weight loss, its associated burden, and perceived weight status in people with cancer. 
  • Validation and real-world assessment of the Functional Assessment of Anorexia-Cachexia Therapy (FAACT) scale in patients with advanced non-small cell lung cancer and the cancer anorexia-cachexia syndrome (CACS). 
  • Visceral leishmaniasis: a model for infection-induced cachexia. 
  • Wasting and macrophage production of tumor necrosis factor/cachectin and interleukin 1 in experimental visceral leishmaniasis. 
  • Weight loss over time and survival: a landmark analysis of 1000+ prospectively treated and monitored lung cancer patients. 
  • What are the criteria for response to cachexia treatment? 
  • Zinc alpha-2-glycoprotein is expressed by malignant prostatic epithelium and may serve as a potential serum marker for prostate cancer. 
• 

  Keywords of People

  • Taylor, Gregory Alan, Professor in Medicine, Integrative Immunobiology